IDH1 and glioblastoma: Primary GBM cells were characterized for the wild-type IDH1/IDH2 status, which helps with prognosis, MGMT methylation status, which indicates the efficacy of current standard of care, and finally, the epigenetic subclass of the samples used, as reported in a previous paper [57].